Resources

Subcutaneous DMPA (DMPA-SC, Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This brief provides an overview of PATH’s research studies assessing the feasibility and acceptability of self-injection in Uganda and Senegal. For more information, please visit www.path.org/dmpa-sc or email FPoptions@path.org.

This document was created to support ministry of health and nongovernmental partners as they develop strategies to introduce and scale up subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) to increase contraceptive options and access. Available in English and French, the publication provides practical guidance based on results, evidence, and learning from the pilot introductions of Sayana Press in four countries in Africa. For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.

Answers to these simple questions will provide an effective 10-part plan to help you achieve important health policy changes and accountability.Hard copies available upon request.

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is an innovative injectable contraceptive that can dramatically expand access and choice for women. The following collection of resources provides an overview of research and experience on the feasibility and acceptability of DMPA-SC among family planning clients and providers. For more information, visit www.path.org/dmpa-sc or email FPoptions@path.org.

This brief outlines the current state of immunization in Uganda and the efforts, investments, and strategies required to meet the commitments made in the Addis Declaration on Immunisation and ensure all Ugandans receive the promise of immunisation.